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Abstract
Background: The n-of-1 trial offers a more methodologically sound approach to determining
optimum treatment for an individual patient than "trials of therapy" routinely conducted in clinical
practice. However, such methodology is rarely used in the UK. This pilot study explores the
acceptability of n-of-1 trials to patients in the UK.
Methods: Patients with osteoarthritis of the knee were recruited to their own 12-week n-of-1
trial comparing either two knee supports or an NSAID with simple analgesic. Patients were
interviewed at the start and completion of their trial to explore reasons for participation,
understanding of the trial design and experiences of participation. Daily diaries were completed to
inform future treatment.
Results: Nine patients participated (5 supports, 4 drugs). Patients were keen to participate,
believing that the trial may lead to personal gains such as improved symptom control and quality of
life. However, recruitment to the pharmacological comparison was more difficult since this could
also entail risk. All patients were eager to complete the trial, even when difficulties were
encountered. Completing the daily diary provided some patients with greater insight into their
condition, which allowed them to improve their self-management. The n-of-1 trial design was
viewed as a 'logical' design offering an efficient method of reaching a personalised treatment
decision tailored to suit individual needs and preferences.
Conclusion: This pilot study suggests that patients perceive the n-of-1 trial as an acceptable
approach to the individualisation of treatment. In addition, further benefits over and above any
gained from the interventions can be derived from involvement in such a study.
Background
In routine clinical practice, when optimum treatment for
an individual patient is uncertain, clinicians frequently
conduct a "trial of therapy", in which the patient is given
a treatment and the subsequent clinical course determines
whether the treatment is deemed effective and continued.
Many factors may mislead the clinician, such as the pla-
cebo effect, the natural history of the illness, patient and
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clinician preferences and the urge of the patient and clini-
cian not to disappoint each other[1]. The single patient, or
n-of-1 trial, offers a more methodologically sound
approach to identify responders and non-responders to
treatment amongst those with chronic and stable condi-
tions and to determine optimum therapy for the individ-
ual [1-3]. Indeed, it has been suggested that the n-of-1 trial
is the study design with the potential to deliver the highest
strength of evidence for making individual treatment deci-
sions[4]. In such a trial, an individual serves as their own
control in assessing the comparative effectiveness of dif-
ferent treatments. This design provides the opportunity to
measure the symptoms that matter to the individual con-
cerned. It is conducted as a randomised, multi-crossover
trial with three or more periods receiving each treatment.
Ideally, the patient and health care providers are blind to
the allocation of treatment within each period.
Previous research has demonstrated that n-of-1 trials can
provide a definitive clinical answer as to future treatment
[5-10]. Nevertheless, they are not widespread within
healthcare and the design is said to be under-
exploited[11]. This is especially the case in the UK. Before
advocating the increased use of such methodology in clin-
ical practice in the UK it is essential to assess its accepta-
bility to patients. Whilst n-of-1 trial methods and
examples of their use in different clinical areas[5-10,12],
are reasonably well documented[1-3,10], little work has
been published exploring the patient's perspective of
being involved in such a trial [5-7]. N-of-1 trials rely on
co-operation between individual health care providers
and patients and there is a suggestion that where such tri-
als fail it is likely to be related to non-compliance or poor
symptom reporting by patients[1]. The time commitment
for patients and health professionals is considerable and
may lead to particular problems with recruitment and
retention. The individual's commitment to the trial is
therefore essential.
This paper reports a pilot study that begins to explore
patients' perspectives of being involved in their own n-of-
1 trial in the UK. Individual trials were conducted with
patients with osteoarthritis (OA) of the knee, comparing
(1) a standard knee support with a heat retaining support,
or (2) a non-steroidal anti-inflammatory drug (NSAID)
(diclofenac) with a simple analgesic (paracetamol).
Methods
Recruitment of patients
Patients attending clinics in the North Bristol Health Care
Trust, with confirmed OA of the knee (Kellgren-Lawrence
radiographic score of 2–4 within the previous 12
months)[13] and use-related pain were eligible. Patients
who had received corticosteroid injections or operations
on their knee in the previous six months were excluded.
Those with known contraindications to paracetamol or
any NSAID, and those taking steroids, warfarin or aspirin
for another medical condition were excluded from the
drug comparisons. The study was approved by the local
medical research ethics committee.
The intention was to recruit around ten patients to their
own 12-week n-of-1 trial, five comparing two knee sup-
ports and five comparing two drugs. The research nurse
initially approached patients via telephone. A letter and
information sheet explaining the study was then sent.
Patients willing to participate attended an appointment
with the research nurse during which the study was dis-
cussed in more detail and informed consent was
obtained. Eligible patients not wishing to participate were
asked if they would talk to a researcher about reasons for
non-participation.
Interventions
Each trial had a total of six treatment periods, three on
each type of intervention considered. The sequence of
treatments was determined by an independent researcher
using computer-generated random numbers and the treat-
ment allocation schedules were kept in consecutive sealed
opaque envelopes held by the research nurse (support tri-
als) or the dispensing pharmacy (drug trials). In the knee
support trials, each treatment period was one-week long
with a one-week 'washout' period between each support.
It was not possible to blind the patient or the research
nurse since the supports could not be made indistinguish-
able due to the thickness and material of the heat retain-
ing support. During these trials, patients continued with
their usual medication. In the drug trials, each treatment
period lasted two weeks with no 'washout' period. Identi-
cal placebos were obtained for the diclofenac and the
paracetamol. In any treatment period patients received
one bottle of an active drug and one of placebo. Patients,
research nurse and consultant were blind to which active
drug was being taken. Patients were requested to take two
500 mg tablets of paracetamol or matching placebo three
times a day and one 50 mg tablet of diclofenac or match-
ing placebo three times a day. Patients stopped taking all
currently prescribed medication for their OA for the dura-
tion of their drug trial but emergency analgesic was avail-
able. The research nurse met with patients at the end of
each treatment period to give them the intervention for
the subsequent period.
Patient interviews
All participating patients were interviewed at the start of
their individual trial and again on completion or termina-
tion. Interviews were qualitative and semi-structured
using open-ended questioning and a topic list. The list
was developed by the research team but updated through-
out the study to incorporate emerging themes. The mainTrials 2007, 8:10 http://www.trialsjournal.com/content/8/1/10
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topics explored were: decision-making surrounding par-
ticipation; understanding of the n-of-1 trial design; expec-
tations prior to commencing; and experiences of
participation. Respondents were able to discuss these
issues in any order, in their own terms, and to introduce
other issues of importance. Interviews lasted between 45
and 90 minutes and were conducted by CP (supports tri-
als) and LB (drug trials) at the patient's home or at hospi-
tal according to the patient's preference.
Interviews were tape-recorded and transcribed verbatim.
All data were anonymised. Transcripts were read carefully
and then coded to identify common themes. Codings
were compared across transcripts and a descriptive coding
framework was devised, which was applied systematically
to all transcripts. This identified key categories of codes.
Descriptive accounts were then produced to explore the
content of each category and to compare and contrast this
within and across interviewees, thus following the general
method of constant comparison[14]. Summary case stud-
ies were also produced for each interviewee. In order to
check consistency of interpretation a sample of transcripts
were coded by two researchers. Data collection and analy-
sis were alternated. Baseline interviews informed follow-
up interviews and findings from knee support trial inter-
views were explored further with those participating in
drug trials.
Daily diaries
Patients completed a daily diary throughout their trial.
This incorporated visual analogue scales for overall pain
and stiffness in the study knee, a patient generated out-
come measure (MYMOP) [15], and the standard disease-
specific Western-Ontario and McMaster University scale
(WOMAC)[16]. On completion of each trial, diary data
were analysed and a summary was prepared for discussion
between the patient and consultant to inform future treat-
ment. These analyses are not presented here since this
paper focuses on the interview data.
Results
Patient recruitment
At the end of 2001, patients were approached to partici-
pate in their own knee support trials. The first five eligible
patients agreed to participate. Patients were invited to par-
ticipate in the drug trials in 2003. Of the first 10 eligible
patients, four gave their consent to participate and six
refused: one patient was caring for their partner and was
concerned about the time involved and becoming ill (this
patient, Mary, agreed to talk to a researcher about her rea-
sons for non-participation); one had participated in the
knee support trials but was not keen to be involved in a
trial of drugs; one was recommended by their GP not to
participate due to co-morbidities; one was not interested
in research; two gave no reason for refusing. Three
patients withdrew before the end of their trial due to intol-
erance to the interventions (Table 1).
Willingness to participate
Interviews began by exploring what had determined each
patient's decision to participate. Primarily, all respond-
ents were motivated by the possibility of deriving per-
sonal gains such as; pain relief, improved quality of life,
and discovery of an effective or more acceptable treat-
ment.
"If there's anything that I could possibly use that was going to
make my quality of life better and I was going to help someone
else at the same time, why not? Because I think surgery is very
invasive and if you can go without it and still have some rea-
sonable quality of life, why not?" [Pansy]
"Well, I says 'well, oh, I'll try that', like, because at the end I'll,
I'm going to find out which is the best, either the, what is it, the
paracetamol, or the other ones, whichever you're going to give
us, at the end I want to find out anyway which is the best
ones...so, I'm going to find sommat out at the end of it
[laughs]" (Interviewer: "so you think it would be quite helpful
for you?") "Yeah." [George]
Some respondents also gave altruistic reasons for partici-
pation:
"That's why I am happy to try, you know, take part in this trial
because you know if it helps, not just if it helps me but if it helps
other people, you know, you have to do trials don't you...really
it's the only way you find out about things isn't it, it's the only
way you go forward is to um by trials and research studies."
[Lyn]
Recruitment to the drug trials was more difficult. Less than
half of those approached agreed to participate compared
to all those approached about the knee support trial.
Some knee support trial participants indicated they would
have been less willing to participate had the intervention
been pharmacological due to possible side effects or dis-
comfort associated with injections. In contrast, wearing a
knee support was perceived as 'unlikely to make things
worse' since the intervention did not interfere with any
current medical or self-management and presented little
inconvenience.
The decision to participate in a drug trial was conditional
upon a perception of low risk. Negative views about med-
icine-taking were mitigated by: knowledge that one could
withdraw from the trial at any time; familiarity with the
drugs due to previous usage; and the 'n-of-1' trial design,
which meant taking tablets for just 2-week periods, since
this was perceived to pose little risk of addiction or 'dam-
age to the system'.Trials 2007, 8:10 http://www.trialsjournal.com/content/8/1/10
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(Interviewer: "You mentioned being worried about getting
addicted to them [paracetamol], things like that, so I was quite
interested that you actually agreed to be in this study as we're
asking you to take paracetamol.") "Yeah but it's not over a
length of time, is it? Where, if I was going to take them every-
day you do get addicted... this is just a fortnight and change and
whatever, so not be too bad... If they [tablets] don't work, if I
get a lot of pain, which I haven't got at the moment, I'll just stop
it and go back on my normal tablets that I'm taking. Simple as
that. Because I ain't going to suffer for nobody." [George]
Participation was also dependent upon the possibility of
personal gain outweighing potential risks. This was illus-
trated by the accounts of two participants who had
exhausted other treatment options and so were 'willing to
try anything' to find a 'solution'. The trial offered the hope
of improving management of their condition and in one
case of avoiding total knee replacement surgery:
"I just think whether it's because I've had these problems for so
many years I just think yes, I'll do anything just to try and kind
of find out if something's going to work." [Rosie]
Reasons for non-participation were not explored in detail
since only one refuser (Mary) agreed to an interview.
However, Mary's account reinforces the centrality of per-
ceived personal risks and gains to individuals' decisions
about participating in an 'n-of-1' trial. Mary was deterred
by the risk of adverse drug side effects in case these ren-
dered her unable to fulfil her caring role. At the same time,
the trial appeared to offer little prospect of gain since she
preferred 'non-medical' self-management of her condi-
tion and was satisfied with how she was coping.
"I do remember reading it and thinking quite hard about it,
and talking to my daughters about it...and she said 'I don't
think it would be a good idea, Mother' [laughs]...You know, in
case I did do one and it did give me problems, you see...and
then I wouldn't be able to, um, be well enough myself, I mean
this is quite a big house as you can see, and I do all the garden
and everything because my husband can't breathe well, he's on
oxygen fifteen hours a day so I got to do absolutely everything..."
(Interviewer: "Did you think at all that it [the trial] might
actually be beneficial to you.") "Er, no I didn't think that at all,
no. I was only worried it wouldn't be beneficial [laughs]. That
was the bit that worried me more because I manage to cope
quite well with the way I do things anyway" (Interviewer: "OK,
so you're sort of quite happy as you are?") "At the moment,
yeah." [Mary]
Practical considerations were of importance to participa-
tion in both trials. These were individual and dependent
upon specific social circumstances, thus demonstrating
the importance of offering flexibility to secure participa-
Table 1: Patient characteristics and trial progress
Namea Age Regular medication 
prior to trial
Trial completion Result of trial Treatment decision
Standard vs heat retaining knee support – trials commencing December 2001 to February 2002
Ann 67 solpadol, meloxicam, 
amitryptiline
Completed Heat retaining support beneficial Continued use of heat 
retaining support
Mel 54 dihydrocodeine, co-
dydramol, amitryptiline
Withdrew after 6 weeks – intolerance to supports No further use of 
supports
Amber 49 no regular medication, 
occasional paracetamol
Completed Heat retaining support beneficial Continued use of heat 
retaining support
Lyn 54 rofecoxib, 
dihydrocodeine, 
paracetamol
Completed No benefit from either support No further use of 
supports
Pansyb 51 rofecoxib Completed No benefit from either support No further use of 
supports
Diclofenac vs paracetamol – trials commencing September 2003 to October 2003
Pansyb 53 Rofecoxib Withdrew after 6 weeks – diclofenac side-effect (stomach pains) Returned to previous 
treatment
Rosie 31 Paracetamol Withdrew after 2 weeks – diclofenac side-effect (mouth ulcers) Returned to previous 
treatment
Jack 59 no regular medication Completed No benefit from either drug No regular medication 
(paracetamol when 
necessary)
George 61 cod liver oil only Completed Diclofenac superior Continued with 
diclofenac
a All names have been changed to maintain patient anonymity
b One patient undertook their own knee support and drug n-of-1 trialTrials 2007, 8:10 http://www.trialsjournal.com/content/8/1/10
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tion. For instance, one participant needed home visits as
transport was a problem and others required appoint-
ments to fit around work commitments.
Eagerness to complete
The potential for personal gain meant participants were
eager to complete their trials. Perseverance was a common
sentiment. All patients in the knee support trials experi-
enced problems with their poor fit, pain and discomfort.
However, they continued to wear the supports and com-
pleted their daily diaries until the end of their trial, with
one exception (Mel).
"That was the only thing that was a bit disappointing [the sup-
ports]. I, I sort of hoped that um you know it might be a little
bit better. But I persevered and you know I, I kept on doing it
you know, for the trial." [Lyn]
"Well I mean I said I would do it so I thought, no I'm going to
stick with this and I will give it, you know, give it a go...I didn't
vary it, she [the nurse] said 7 days [wearing the support]...I've
got to admit that I was just thinking oh I've only another day
and I can have a bit of relief from this." [Mel]
Two drug trial participants found it difficult to take so
many tablets and had to withdraw due to side-effects
(Table 1), however, both were willing to re-start the trial
and were disappointed by having to withdraw because
this removed their hope of finding an effective treatment.
(Interviewer: "Will you be disappointed if you're taken out of
the trial?") "I don't know, probably not because I wouldn't have
to take the tablets but then I would be because I wouldn't know,
it would be a bit like well what are you going to try me on now?"
(Interviewer: "Are there many of other treatment options for
you as far as you know?") "Not at the moment no, I'm seeing
this physio but no I don't think there's anything at the
moment." [Rosie]
Daily diaries were completed with very little missing data
by all patients and were seen as quick and easy to com-
plete. Only one participant found this tedious.
Outcomes and added benefits
All patients who completed their trial attended a feedback
meeting with their consultant where the results of the dia-
ries were discussed and used to inform a joint decision
regarding future treatment (Table 1).
Despite the fact that Pansy and Lyn experienced no treat-
ment benefits, both felt there had been benefits of partic-
ipating. Lyn gained more insight into her problem, which
led her to seek surgical help.
"Um, I think one of the main things I noted was it, it made me
more aware of my problems and aches and pains and it's made
me actually decide even though Dr C suggested several times,
you know, how do I feel about getting you know, having a knee
replacement. And I've been putting it off and putting it off but
I'm now feeling as though I really ought to do something about
it." [Lyn]
For Pansy, who experienced side effects during her drug
trial and withdrew early, the trial was still informative.
"I've learned not to mess with my medication again [laughs]
any tablets, yeah, I'm not a keen tablet taker anyway, just take
them through necessity, um, but it just reinforced problems that
I'd had previously which you tend to forget about taking tablets
and how long it, you know, it had taken me to sort them out, so
in a way it was a relief to get back to taking something that I
know was going to have some improvement albeit, not as good
as possibly I would like, but um, yes." [Pansy]
Some respondents found that diary completion provided
insight into their condition and helped identify adjust-
ments to daily activities that could be made in order to
gain better self-management of symptoms.
"...it reinforces what actually happened on those days and, and
I suppose also again, certain days the pain was at a certain
level, and on others [pause] and I could also identify what I'd
done to increase that if you know what I mean, so to me, it was
helpful in many ways, to know what I should and should not be
doing." [Pansy]
During her knee support trial, Pansy noticed that she
seemed to get worse at weekends and was pleased to see
this pattern was evident in the diary scores.
"No that was interesting to see that, 'cause it was only as I
started doing that, that it suddenly came to me, well I thought
well I'm sure it's getting worse weekends, why? And that's why
I identified that, that it's everything that I do during the week
I'm doing to extremes at the weekends." [Pansy]
This additional benefit was also perceived by Amber, who
identified that she needed to go for more frequent short
walks in order to better control her symptoms.
"End of every sort of week I sort of go back through it [the
diary] and look through and you know, Oh yeah I did a bit of
extra walking that week and my knee played up but if I didn't
do enough walking my knee played up so, I've learnt to sort of
do 20 minutes walking now and then sort of stop ...I've learnt
a bit out of it." [Amber]Trials 2007, 8:10 http://www.trialsjournal.com/content/8/1/10
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Acceptability and understanding of the trial design
In general, participants viewed medical research favoura-
bly and regarded it as essential for reaching conclusions
about the effectiveness and safety of treatments. Although
most had a limited understanding of the 'n-of-1' trial
design, several compared it to participation in a conven-
tional randomised trial and understood that they would
receive both treatments, which they regarded as more
favourable.
Above all, they emphasised the existence of variation
between individuals in their responses to treatment,
believing that 'everyone is different' (Jack) and that 'what
works for some people isn't going to work for others'
(George). In this sense, comparing against oneself rather
than against others was perceived as more 'logical' and
likely to reveal an accurate answer.
(Interviewer: "She [research nurse] said this would be a trial in
which you would be compared with yourself.") "Yes, oh that
makes a lot more sense than comparing me, or someone else to
me, or me to someone else because we're all different. We're all
totally different. Me's me and you's you as it were...that's got to
be the way of doing it. Let's say if you get twenty people in a
room and they've all got a headache. So you say to them, 'right
you can have two paracetamol, and you can have a placebo',
maybe half the ones that had the paracetamol it won't make
any difference to anyway because they don't affect them so what
conclusion can you come to?...because we're all different. Some
people can't even take paracetamol because they have a violent
reaction to it and I've taken six at a time and even then it hasn't
had much affect." [Jack]
In turn, participants were able to view the trial as 'being
about me' (Pansy) and as offering an efficient method of
reaching a personalised treatment decision that is tailored
to suit individual needs and preferences.
(Interviewer: "Do you think they [n-of-1 trials] are a good
idea?") "Well yes I can say that about this one. I think if it's
going to benefit you. It depends what people think but I think
this one especially because it was going to benefit me at the end
of it to know which tablet was going to be the best one for me.
Yes, so yes it just depends what the trial is, doesn't it?" [Rosie]
(Interviewer: "Can you see a point in having one and then
another [treatment]?") "Well yeah, well its just like anything
isn't it? Like with food you eat. You try Cabbage, you don't like
that, so you try broccoli. Oh that's quite a funny way of equat-
ing it really but you don't know until you've tried anyway do
you?" [Amber]
Two participants (Jack and George) also described the n-
of-1 trial as 'fairer' on the basis that each individual would
have the opportunity to benefit from an active treatment,
while this is not the case in a conventional trial.
"You could have twenty people in a trial. Ten have a placebo,
ten have whatever the tablet is, the one that's going to cure
it...there would be that group of people that never got treated
for it." (Interviewer: "so does this seem fairer this trial [n-of-
1]?") "Of course it is. It just seems odd to me that they say this
[n-of-1] is like a new study. I would of thought one would of
done that ages ago. I always think it's rather odd and feel sorry
for the person that's getting the placebo if they've got a problem
because its not doing anything for them." [Jack]
These factors meant that participation in an n-of-1 trial
was likely to yield personal benefit.
Discussion
This pilot study suggests the acceptability of using n-of-1
trials within secondary care in the UK. Participants viewed
the n-of-1 trial as a logical, accurate and 'fair' study design.
They recognised and valued the personalised nature of the
trial and that it had the potential to offer personal gain,
namely improved treatment. Indeed, this possibility
meant that individuals were keen to participate and per-
sist with the trial, even where difficulties were encoun-
tered. These findings indicate that recruitment to n-of-1
trials is feasible, though barriers were encountered where
the intervention was pharmacological due to perceived
risks. Further, flexibility (for example, in relation to the
time and location of appointments) was identified as
important to trial participation and this can be accommo-
dated more easily within the context of an n-of-1 trial
design. The findings also suggest that further benefits over
and above any gained from the intervention can be
derived from involvement in such a study. Some partici-
pants gained greater insight into their condition, which
improved their self-management. Three patients with-
drew before the end of their n-of-1 trial because of intol-
erance to the interventions. Even for such individuals
future treatment is informed from participation in an n-
of-1 trial.
Of course, the pilot nature of this study and the sample
size involved means that a full exploration of views is
unlikely to have been achieved but the findings support
and complement other similar research, which has found
patient response to be very positive and established evi-
dence of consumer demand for n-of-1 trials outside the
UK[5,6,8,9,12]. Nickles et al recently published the results
of a qualitative study conducted in Australia, where n-of-
1 trials are more widely recognised and established[7]. As
in this study, Nickles et al found that patient participation
led to better understanding and management of their con-
dition. The present study has extended this work to the UK
where the uptake of such trials has been much slower.Trials 2007, 8:10 http://www.trialsjournal.com/content/8/1/10
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Reported n-of-1 trials have evaluated pharmacological
treatments in a range of conditions[5-10,12]. However,
few report their use for non-pharmacological treatments
within health services. An obvious limitation of the knee
support trials, was the lack of blinding and the potential
for a patient's pre-conceived preferences and beliefs to
bias diary entries. The 'placebo effect' has been estimated
to be responsible for up to 30% of many treatment effects
observed in conventional randomised trials[17]. In the
context of an n-of-1 trial, for some individuals it may be
unlikely that prior beliefs can be maintained for several
treatment changes if they are not substantiated by real
clinical benefits. For others, a placebo effect experienced
in the early part of an n-of-1 trial may perpetuate prior
beliefs for later treatment periods. If prior preferences and
beliefs are maintained for the duration of a trial then there
may still be a benefit (albeit non-clinical) from continu-
ing with a specific treatment choice. The impact of an
unblinded n-of-1 trial will inevitably depend on both the
strength of prior beliefs and the individual. In any case,
the presence of multiple treatment periods and structured
data collection throughout the study means that the n-of-
1 design remains methodologically superior to "trials of
therapy" even in the absence of blinding.
The time and cost involved in conducting an n-of-1 trial
means that they cannot be performed for all patients for
whom a treatment decision is sought. In addition, such
trials are only appropriate for patients with chronic and
stable conditions and (due to potential carry-over effects
from one treatment period to another) for interventions
with rapid effect and termination of effect. Due to the
presence of multiple treatment periods, outcomes cannot
be permanent states such as death. Despite these limita-
tions, when optimal treatment for an individual patient is
in doubt and the above criteria are met, the n-of-1 trial
offers a methodological improvement to standard clinical
practice, essential in the context of evidence-based medi-
cine[4]. Such methods may also improve the doctor-
patient relationship by encouraging shared-decision mak-
ing, which is especially important in the management of
chronic disease.
In conclusion, this pilot study suggests that the n-of-1 trial
is an acceptable approach to the individualisation of treat-
ment in the UK. Moreover, from the patient's perspective,
involvement in such a trial may result in additional bene-
fits. An important next step is to explore the issues raised
in this study with a larger and more diverse sample. Fur-
ther attention should also be directed towards discovering
reasons for refusal, especially when considering pharma-
cological interventions. Similar research should be con-
ducted within primary care in the UK, though it is likely
that patient perspectives would be similar to those
observed here and by Nikles et al[7]. The use of n-of-1 tri-
als in clinical practice is likely to be increased by better
understanding of their purpose and potential amongst all
stakeholders, not just the patient, and the development of
dedicated n-of-1 services.
List of abbreviations
RCT – Randomised controlled trial
NSAID – Non-steroidal anti-inflammatory drug
OA – Osteoarthritis
MYMOP – Measure your medical outcome profile ques-
tionnaire
WOMAC – Western Ontario and McMaster Universities
Osteoarthritis Index
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All of the authors have been involved in either the concep-
tion and design of the research (SB, CP, PD) and/or the
analysis and interpretation of the data (SB, CP, LB, GW).
All authors have been involved in the drafting of the paper
and all have seen and approved the final manuscript.
Acknowledgements
This study was funded through an MRC Research Initiation Grant. The 
authors would like to thank Julie Haynes and Paul Creamer for all their 
work throughout the study and Cathy Pope for her involvement in the 
design of the study. The Department of Social Medicine at the University of 
Bristol is the lead centre for the Medical Research Council's Health Services 
Research Collaboration.
References
1. Sackett DL, Haynes RB, Tugwell P, Guyatt G: Clinical Epidemiology: a
basic science for clinical medicine 2nd edition. Boston, Little Brown;
1995. 
2. Guyatt G, Sackett D, Adachi J, Roberts R, Chong J, Rosenbloom D,
Keller J: A clinician's guide for conducting randomized trials
in individual patients.  CMAJ 1988, 139:497-503.
3. Johannessen T, Petersen H, Kristensen P, Fosstvedt D: The control-
led single subject trial.  Scand J Prim Health Care 1991, 9:17-21.
4. Guyatt GH, Haynes RB, Jaeschke RZ, Cook DJ, Green L, Naylor CD,
Wilson MC, Richardson WS: Users' Guides to the Medical Liter-
ature: XXV. Evidence-based medicine: principles for apply-
ing the Users' Guides to patient care.  JAMA 2000,
284:1290-1296.
5. Nikles CJ, Glasziou PP, Del Mar CB, Duggan CM, Clavarino A, Yelland
MJ: Preliminary experiences with a single-patient trials serv-
ice in general practice.  Med J Aust 2000, 173:100-103.
6. Duggan CM, Mitchell G, Nikles CJ, Glasziou PP, Del Mar CB, Clava-
rino A: Managing ADHD in general practice. N of 1 trials can
help!  Aust Fam Physician 2000, 29:1205-1209.
7. Nikles CJ, Clavarino AM, Del Mar CB: Using n-of-1 trials as a clin-
ical tool to improve prescribing.  Br J Gen Pract 2005, 55:175-180.
8. Larson EB, Ellsworth AJ, Oas J: Randomized clinical trials in sin-
gle patients during a 2-year period.  JAMA 1993, 270:2708-2712.
9. Wolfe B, Del RE, Weiss SL, Mendelson A, Elbaga TA, Huser FJ, Reit-
berg DP: Validation of a single-patient drug trial methodologyPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Trials 2007, 8:10 http://www.trialsjournal.com/content/8/1/10
Page 8 of 8
(page number not for citation purposes)
for personalized management of gastroesophageal reflux
disease.  J Manag Care Pharm 2002, 8:459-468.
10. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, New-
house MT: The n-of-1 randomized controlled trial: clinical
usefulness. Our three-year experience.  Ann Intern Med 1990,
112:293-299.
11. Senn S: Individual therapy:  new dawn or false dawn?  Drug Infor-
mation Journal 2001, 35:1479-1494.
12. Kent MA, Camfield CS, Camfield PR: Double-blind methylpheni-
date trials: practical, useful, and highly endorsed by families.
Arch Pediatr Adolesc Med 1999, 153:1292-1296.
13. KELLGREN JH, LAWRENCE JS: Radiological assessment of
osteo-arthrosis.  Ann Rheum Dis 1957, 16:494-502.
14. Glaser BG, Strauss AL: The discovery of grounded theory Chicago,
Aldine; 1967. 
15. Paterson C, Langan CE, McKaig GA, Anderson PM, Maclaine GD,
Rose LB, Walker SJ, Campbell MJ: Assessing patient outcomes in
acute exacerbations of chronic bronchitis: the measure your
medical outcome profile (MYMOP), medical outcomes
study 6-item general health survey (MOS-6A) and EuroQol
(EQ-5D).  Qual Life Res 2000, 9:521-527.
16. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW: Val-
idation study of WOMAC: a health status instrument for
measuring clinically important patient relevant outcomes to
antirheumatic drug therapy in patients with osteoarthritis of
the hip or knee.  J Rheumatol 1988, 15:1833-1840.
17. Sackett DL: Inference and decision at the bedside.  J Clin Epide-
miol 1989, 42:309-316.